Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.

Abstract excerpt

Aberrations in oncogene RET (rearranged during transfection) have been found to be the cause of different kinds of malignancies, especially in lung and thyroid cancers. Targeted therapy of RET-altered cancers using multi-kinase inhibitors (MKIs) has demonstrated limited clinical efficacy due to off-target toxicity. In May 2020, the U.S. Food and Drug Administration (FDA) approved a novel specific RET inhibitor...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung
• Share to Lung Neoplasms
• Share to Mutation